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Introduction
One of the most thoroughly studied metastasis-associated
systems in patients with breast cancer is the plasminogen acti-
vation system. This system comprises of, among others, the
urokinase-type plasminogen activator (uPA) and its main inhib-
itor (PAI-1), and is primarily involved in extracellular matrix
degradation (1). Most studies have focused on the prognostic
value of uPA and PAI-1 (1-6). The potential predictive value of
tumor levels of uPA and PAI-1, i.e. the power to predict therapy
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with lower uPA:PAI-1 complex levels (P=0.035). Furthermore,
in the multivariate regression analysis a significant lower rate of
response to first-line endocrine therapy was found in patients
with high uPA:PAI-1 complex levels compared to patients with
low uPA:PAI-1 complex levels (odds ratio (OR)=0.27, 95% CI,
0.09-0.59, P=0.018), in addition to the predictive impact of the
steroid hormone receptor (ER/PgR) status (OR=2.68, 95% CI,
1.08-6.63, P=0.033). Complex levels did not predict efficacy of
chemotherapy in patients with advanced breast cancer. The
results show that the plasminogen activation system affects the
response to endocrine therapy independent of steroid hor-
mone receptor status and may be of help to further refine the
indication for this treatment in individual patients. Further 
studies are warranted to explain this underlying resistance to
endocrine therapy when uPA:PAI-1 levels are high.
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Summary
It has been shown that urokinase-type plasminogen activator
(uPA) and its main inhibitor (PAI-1) have predictive value for
therapy success in advanced breast cancer. Levels of the com-
plex between uPA and PAI-1, formed when both molecules are
in their active form, might have superior predictive power.
Here, we investigate the association between levels of uPA:PAI-
1 complex and rate of response to first-line systemic therapy
for advanced breast cancer. Tumor tissues of 170 patients with
advanced breast cancer were analyzed for uPA:PAI-1 complex
concentrations using a quantitative enzyme-linked immunosor-
bent assay. The patients received either endocrine therapy
(n=96) or chemotherapy (n=74) as first-line treatment after
diagnosis of advanced disease. Of the endocrine treated
patients, those with high levels of uPA:PAI-1 complex showed a
shorter progression-free survival (PFS) compared to patients
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success, has been investigated in three breast cancer studies (7-
9). Harbeck, et al. investigated the predictive value of uPA and
PAI-1 (7, 8), showing that patients with high tumor tissue uPA
levels in combination with high PAI-1 levels benefited more
strongly from conventional adjuvant systemic therapy, particu-
larly from chemotherapy, than those with low levels. So far,
there is only one study addressing the correlation between
tumor levels of uPA and PAI-1 and the response to first-line
tamoxifen therapy in advanced breast cancer patients (9). The
results of that study showed that increasing tumor levels of uPA
and PAI-1 were predictive for poor response to tamoxifen in
patients with advanced breast cancer.
The plasminogen activation system is a multifactorial
system and in addition to uPA and PAI-1, uPA:PAI-1 complex is
present in tumor tissue extracts (10, 11). As complex formation
between uPA and PAI-1 occurs only when both molecules are in
their active form, one might assume that the level of uPA:PAI-1
complex represents previously active uPA and PAI-1.
Importantly, the active forms of these components are involved
in tumor growth, invasion and metastasis. Therefore, selective
assessment of uPA:PAI-1 complex levels in tumor tissue could
yield even more predictive information than total uPA and/or
PAI-1 levels. The prognostic value of uPA:PAI-1 complex has
been evaluated in invasive breast cancer in two retrospective
studies (12, 13). To date, however, there are no studies on the
predictive value of uPA:PAI-1 complex levels for response to
systemic therapy in advanced breast cancer.
The purpose of this retrospective study was to assess the
predictive value of tumor uPA:PAI-1 complex levels on the effi-
cacy of systemic therapy in patients with advanced breast can-
cer and to compare it with the predictive impact of uPA and
PAI-1. For this purpose, patients with breast cancer who devel-
oped distant metastases during follow-up and were treated with
palliative first-line endocrine- or first-line chemotherapy were
included in this study.
Patients and methods
Patients
A series of 170 patients with primary breast cancer who under-
went resection of their primary tumor between January 1987
and December 1996, and who subsequently developed distant
metastases were included. All patients were treated with first-
line endocrine therapy (n=96) or chemotherapy (n=74). The
median follow-up time of all patients and patients still alive
from start of systemic therapy for advanced disease was 34
months (range 2-180 months) and 38 months (range 2-180
months), respectively. The median age was 55 years (range 
28-86 years) at the time of surgery of the primary tumor. Further
characteristics of patients and tumors are listed in Table 1.
First-line systemic treatment
First-line endocrine therapy was given to 96 patients. These
patients received tamoxifen (n=82), ovarian ablation (n=10),
aromatase inhibitors (n=3) or medroxy-progesterone acetate
(n=1). Nineteen of the patients who received first-line endocrine
therapy had received prior adjuvant chemotherapy. However,
none of these patients had received adjuvant endocrine therapy
nor had become postmenopausal due to the adjuvant chemo-
therapy. Further, none of the patients were exposed to neoadju-
vant therapy.
At the start of first-line endocrine therapy, 61 of the patients
(64%) had an estrogen receptor positive (ER+)/progesterone
receptor positive (PgR+) tumor, 11 (11%) had an ER+/PgR neg-
ative (PgR-) tumor, 7 (7%) had an ER negative (ER-)/PgR+
tumor, 15 (16%) had an ER-/PgR- tumor and the ER/PgR 
status of 2 (2%) was unknown. The patients who received 
first-line endocrine therapy had a median age of 58 years (31-86
years) at start of first-line therapy and the median follow-up
time from this point of patients still alive was 46 months (range
2-180 months).
Table 1: Categorical distributions of baseline characteristics in
patients treated with first-line endocrine therapy or first-line
chemotherapy.
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Seventy-four patients were treated with first-line chemo-
therapy for advanced disease. This therapy consisted of classi-
cal cyclophosphamide, methotrexate, 5-fluorouracil (CMF,
n=43) or 5-fluorouracil, epirubicin/adriamycin, and cyclophos-
phamide (FEC/FAC, n=31). Of these patients, 36 (50%) had an
ER-/PgR- tumor, 3 (4%) had an ER-/PgR+ tumor, 11 (15%) had
an ER+/PgR- tumor and 22 (31%) had an ER+/PgR+ tumor.
Fifteen of the patients who were treated with first-line chemo-
therapy had received prior adjuvant chemotherapy, and fifteen
adjuvant endocrine therapy. The patients who received first-line
chemotherapy had a median age of 48 years (28-81 years) at
start of first-line chemotherapy. The median follow-up time of
patients still alive was 28 months (range 5-178 months). 
Steroid hormone receptor and total protein
assays
Tumor specimens were drawn from a pool of frozen specimens
(stored in liquid nitrogen) originally submitted to our laborato-
ry for steroid-hormone receptor analysis. Processing of the
tumors was performed as described previously (14). ER and
PgR levels were determined with ligand binding assay in cyto-
sols (14). The cut-off level used to classify tumors as ER or PgR
positive or negative was 10 fmol/mg cytosolic protein, the pro-
tein was measured according to Lowry (15) with bovine serum
albumin as a standard.
Determination of the antigen levels of uPA,
PAI-1 and uPA:PAI-1 complex
We used ELISAs developed by our department for uPA and
PAI-1 (16) and for the uPA:PAI-1 complex (10). These ELISAs
are based on a combination of four polyclonal antibodies (raised
in four different animal species, i.e. duck, chickens, rabbits and
goat), which were employed in a sandwich assay format. The
polyclonal antibodies raised in chickens and rabbits are specifi-
cally directed against uPA and PAI-1. The details of the assays,
including those of the specificity and performance, have been
described elsewhere (10, 16).
Data analysis
To analyze interrelations between uPA, PAI-1 and uPA:PAI-1
complex and various traditional parameters, Spearman rank cor-
relations (rs) were calculated for continuous variables and the
Kruskal-Wallis test for ordered variables, followed by a
Wilcoxon-type test for trend if appropriate.
The three markers were categorized in order to study their
possible relationship with progression-free survival (PFS) time
(here defined as the time from the start of the first-line therapy
until the start of a next therapy or until the time of death). The
median value of uPA, PAI-1 and uPA:PAI-1 complex was used
as the cut off value in the statistical analyses. Further division of
the marker values in tertiles or quartiles resulted in progressive-
ly smaller subgroups, which lead to a significant loss of power.
uPA, PAI-1 and uPA:PAI-1 complex were also analyzed as log-
transformed continuous variables.
In univariate and multivariate logistic regression analysis,
the relation with response-to-therapy was examined in the
group of 96 patients who received first-line endocrine therapy
and in the group of 74 patients that received first-line chemo-
therapy. These analyses were also performed in a subset of 82
of the endocrine treated patients that received tamoxifen as part
of first-line endocrine therapy, to test also a more uniform
group. Multivariate analysis was performed for all factors that
were analyzed in univariate analysis, with stepwise removal of
non-significant factors based on the likelihood ratio. Odds ratios
(OR) were calculated and presented with their 95% confidence
intervals (95% CI). Overall response was defined as either a
complete remission (disappearance of disease), partial remis-
sion (more than 50% decrease in product of longest diameter
times its perpendicular diameter of measurable parameters) or
minor response (more than 25%, but less than 50%, decrease in
size of measurable parameters).
For the survival rate analyses PFS time was used as follow-
up parameter. The method of Kaplan and Meier was used to
generate the survival curves (17). The log-rank test was used to
test for differences.
For the analyses, classifications were made for the steroid
hormone receptor status (ER and PgR <10 fmol/mg protein, i.e.
negative receptor-status, versus ER and/or PgR ≥10 fmol/mg
protein, i.e. positive receptor-status). All computations were
done with the SPSS statistical package (release 10.0.5,
November 1999). Two-sided P-values below 0.05 were consid-
ered to be statistically significant.
Results
Distribution of uPA, PAI-1 and 
uPA:PAI-1 complex
ELISAs were used to determine the antigen levels of uPA, PAI-
1 and uPA:PAI-1 complex in the tumor cytosols. The cytosolic
uPA content varied from 0.00 to 9.03 ng/mg protein (median
0.50 ng/mg protein) in the 170 tumors. The cytosolic levels 
of PAI-1 complex ranged from 0.00 to 30.00 ng/mg protein,
with a median value of 1.88 ng/mg protein. A wide range of
concentrations of uPA:PAI-1 complex, ranging from 0.000 to
1.635 ng/mg protein, was observed (median 0.091 ng/mg pro-
tein). Table 2 shows the median levels and quartiles of uPA,
PAI-1 and uPA:PAI-1 complex in subgroups of tumors.
Correlations
The correlation between the cytosolic uPA levels and the PAI-1
levels was statistically significant (rs=0.490, P<0.001).
Significant correlations were also found between the levels of
uPA:PAI-1 complex and uPA levels (rs=0.531, P<0.001) and
uPA:PAI-1 complex and PAI-1 levels (rs=0.665, P<0.001).
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Table 2 shows the relationships of uPA, PAI-1 and uPA:PAI-1
complex with patient and tumor characteristics. The uPA, PAI-1
and uPA:PAI-1 complex tumor levels were higher in ER and
PgR-negative tumors compared with ER and/or PgR-positive
tumors (P=0.046, P=0.044 and P=0.002, respectively). Within
the ER and/or PgR positive tumors, no correlation was found
between uPA, PAI-1 and uPA:PAI-1 complex levels and ER
absolute levels (P=0.776, P=0.456 and P=0.801, respectively)
or PgR absolute levels (P=0.077, P=0.703 and P=0.115, respec-
tively). The tumor levels of all three markers, uPA, PAI-1 and
uPA:PAI-1 complex, showed a significant association with dis-
ease-free interval, i.e. the levels were higher in patients with a
relapse within 1 year after the primary diagnosis of breast can-
cer compared with patients with a disease-free interval of ≥1
year (P=0.051, P=0.049 and P=0.046, respectively).
Patients treated with endocrine therapy
Of the 96 patients who had first-line endocrine therapy for
advanced disease, 51% responded. At a median follow-up of 46
months, 11 (11%) of the patients were still on first-line endo-
crine therapy. The remaining 85 (89%) of the patients had tumor
progression after a median duration of 8 months (range 1-68
months).
Table 3 shows the response rates to first-line endocrine ther-
apy in subgroups defined by ER/PgR status and uPA:PAI-1
complex tumor levels. The response rate to first-line endocrine
therapy was 11% in patients with high uPA:PAI-1 complex lev-
els and ER and PgR negative tumors, 14% with low uPA:PAI-1
complex and negative ER and PgR status, 35% in patients with
high uPA:PAI-1 complex levels and positive ER and/or PgR
status and 72% in patients with low uPA:PAI-1 complex levels
Table 2: Correlations
of uPA, PAI-1 and
uPA:PAI-1 complex
with patients and
tumor characteristics.
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and ER and/or PgR positive tumors. The response rates to first-
line endocrine therapy for patients with ER+/PgR+ patients
(n=61) in subgroups defined by uPA:PAI-1 complex tumor lev-
els, were 37% in patients with high uPA:PAI-1 complex levels
and 70% in patients with low uPA:PAI-1 complex levels (data
not shown).
The rate of response to endocrine therapy defined by each
individual clinicopathological parameter is listed in Table 4.
The response rate of patients with high tumor uPA:PAI-1 com-
plex levels was 29% and in the group of patients with low tumor
uPA:PAI-1 complex levels 62%.
Furthermore, Table 4 shows the results of the logistic
regression analyses for response to first-line endocrine therapy
in patients with advanced breast cancer. In the univariate analy-
sis, postmenopausal patients and patients with positive ER
and/or PgR tumors had a significant higher rate of response to
endocrine therapy than patients who were premenopausal or had
ER and PgR-negative tumors (OR=3.02, P=0.051 and
OR=2.85, P=0.022, respectively). In addition, increased cyto-
solic levels of uPA:PAI-1 complex were also related to a lower
response rate (OR=0.43, 95% CI, 0.21-0.81, P=0.015). There
was also a significant association between higher uPA:PAI-1
Table 3: Response
rate to first-line endo-
crine therapy by
ER/PgR status and
tumor levels of
uPA:PAI-1 complex.
Table 4: Univariate
and multivariate 
logistic regression
analysis for response
to first-line endocrine
therapy in patients
with advanced breast
cancer.
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complex levels and reduced response rate when this marker was
used as log-transformed continuous variable (P=0.031). Neither
uPA nor PAI-1 was significantly associated with rate of
response to first-line endocrine therapy.
To investigate the independent relation of tumor levels of
uPA, PAI-1 and uPA:PAI-1 complex with the rate of response to
endocrine treatment in advanced breast cancer, multivariate
logistic regression analysis was used (Table 4). Increased levels
of uPA:PAI-1 complex levels were associated with a poor rate
of response (OR=0.27, 95% CI, 0.09-0.59, P=0.018). In addi-
tion to uPA:PAI-1 complex, ER and PgR negativity was asso-
ciated with a poor response rate in the multivariate analysis (ER
and/or PgR positive: OR=2.68, 95% CI, 1.08-6.63, P=0.033).
Subsequently, a logistic multivariate regression analysis was
performed in which uPA, PAI-1 and uPA:PAI-1 complex were
added as log-transformed continuous variables. In this second
multivariate analysis, the contributions of ER/PgR status
(OR=2.54, 95% CI, 1.24-6.41, P=0.026) and uPA:PAI-1 com-
plex (OR=0.22, 95% CI, 0.11-0.57, P=0.014) were statistically
significant as well. 
A logistic multivariate model was also prepared separately
for uPA and PAI-1 without inclusion of uPA:PAI-1 complex. In
the final multivariate model only ER/PgR status was associated
with response rate (OR=2.66, 95% CI, 1.07-6.61, P=0.035),
while uPA and PAI-1 were both not related. 
In the Kaplan-Meier analysis of all patients who received
endocrine therapy, patients with high tumor levels of uPA:PAI-
1 complex showed a significantly shorter PFS compared with
patients with lower uPA:PAI-1 complex tumor levels (Fig. 1,
P=0.035, log-rank). uPA and PAI-1 were not associated with
PFS (P=0.998, log-rank and P=0.589, log-rank, respectively).
The rate of response was 48% in the subset of 82 patients
who were treated with tamoxifen. In the multivariate analysis
for response to tamoxifen, uPA:PAI-1 complex was again a sig-
nificant predictor of a poor rate of response (OR=0.37, 95% CI,
0.13-0.76, P=0.023), in addition to ER/PgR status (OR=2.41,
95% CI, 1.04-7.36, P=0.038). In the multivariate analysis in
which uPA:PAI-1 complex was added to the model as a log-
transformed continuous variable instead of a dichotomized var-
iable, the contribution of uPA:PAI-1 complex was still statisti-
cally significant (OR=0.43, 95% CI, 0.26-0.73, P=0.009),
together with ER/PgR status (OR=2.52, 95% CI, 1.27-6.19,
P=0.031).
Patients treated with chemotherapy
Of the 74 patients treated with first-line chemotherapy, 38
(51%) responded. In the group of patients who were treated
with CMF (n=43) 46% responded and in the group of patient
who were treated with FEC/FAC (n=31) 58% responded. At a
median follow-up of 28 months after start of first-line chemo-
therapy, 3% of the patients did not yet have progressive disease.
The remaining 97% of the patients had tumor progression after
a median duration of 5 months (range 1-67 months).
In Kaplan-Meier analysis of the 72 patients who were treat-
ed with first-line chemotherapy, cytosolic levels of uPA, PAI-1
and uPA:PAI-1 complex were not related with PFS (P=0.086,
P=0.678 and P=0.701, log-rank, respectively; data not shown).
The relation of uPA, PAI-1 and uPA:PAI-1 complex with
response-to-therapy in advanced breast cancer was investigated
using univariate logistic regression analysis. The cytosolic lev-
els of uPA, PAI-1 and uPA:PAI-1 complex, neither when ana-
lyzed as log-transformed continuous (P=0.122, P=0.537 and
P=0.336, respectively) nor as dichotomized variables (P=0.244,
P=0.167 and P=0.274, respectively), were significantly related
with the rate of response. Furthermore, none of the other inves-
tigated established prognosticators were significantly associated
with the response rate to first-line chemotherapy (data not
shown), except for the disease-free interval. That is, patients
with a disease-free interval ≥1 year had a significant higher rate
of response to chemotherapy than patients with disease-free
interval <1 year (OR=2.74, 95% CI, 1.05-7.18, P=0.040). Since
uPA, PAI-1 and uPA:PAI-1 complex were shown not to be sig-
nificantly associated with the rate of response in univariate anal-
ysis, logistic multivariate analysis was not performed. A similar
result was found, when all aforementioned analyses were per-
Figure 1: Progression-free survival (PFS) after the start of
endocrine therapy as a function of cytosolic tumor levels of
uPA:PAI-1 complex: low, <0.091 ng/mg protein; high, ≥0.091 ng/mg
protein.
“At risk” indicates the number of patients at risk in each group.
Patients at risk at 0, 12, 24 and 36 months are indicated.
At risk:
Complex-low 51 19 9 4
Complex-high 45 10 4 2
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formed with the exclusion of the 15 patients treated with adju-
vant chemotherapy. 
Discussion
In this retrospective study, the predictive value of uPA:PAI-1
complex levels in tumor tissue with respect to efficacy of first-
line endocrine therapy and first-line chemotherapy was evaluat-
ed in 170 patients with primary breast cancer who developed
distant metastases during follow-up. Increased tumor levels of
uPA:PAI-1 complex were significantly associated with a short-
er PFS after start of first-line endocrine treatment. Furthermore,
uPA:PAI-1 complex levels were significantly related with the
rate of response to first-line endocrine therapy, in addition to the
predictive impact of ER/PgR status. In contrast, tumor levels of
uPA and PAI-1 were not associated with PFS during/with first-
line endocrine therapy nor with the rate of response to first-line
endocrine therapy.
There are two previous studies that focussed on the prog-
nostic value of the uPA:PAI-1 complex (12, 13). These studies
showed conflicting results. Pedersen, et al. reported that high
levels of uPA:PAI-1 complex were associated with a favorable
prognosis in the univariate analysis. They included 342 patients
of whom more than 50% received adjuvant systemic therapy,
which makes it difficult to draw conclusions about the true
prognostic impact of uPA:PAI-1 complex, as actually a possible
predictive impact has also been taken into account (12). In the
study by Sten-Linder, et al., no information can be found on
adjuvant systemic therapy, but since in their study 45% of the
total group of patients (n=233) was node-positive, it is likely
that at least a substantial part of these patients received adjuvant
systemic therapy (13). Furthermore, the investigators did not
perform a multivariate analysis. They found that high uPA:PAI-
1 complex levels were associated with a poor prognosis.
Here, we showed that breast tumors with high uPA:PAI-1
complex levels were less sensitive to endocrine therapy. We and
others (4-6) observed a significant inverse correlation between
levels of components of the plasminogen activation system and
the steroid hormone receptor status. Given the higher uPA:PAI-
1 complex levels in ER/PgR-negative tumors, one might specu-
late that there may be a relative lower ER/PgR content in the
ER/PgR-positive tumors with high uPA:PAI-1 complex levels
compared to those with low uPA:PAI-1 complex levels, which
might consequently also influence the response to endocrine
therapy. For that reason, we also analyzed whether the absolute
ER/PgR levels were correlated with the uPA:PAI-1 complex.
We observed that within the ER and/or PgR positive tumors no
correlation could be found between the absolute ER/PgR levels
and uPA:PAI-1 complex levels. In our view, the exclusion of
this correlation considerably strengthens the conclusion that the
relation between uPA:PAI-1 complex and rate of response to
first-line endocrine treatment is truly independent of ER/PgR
status. For endocrine therapy, the expectation is that slowly
growing tumors better respond to endocrine therapy. Foekens, et
al. found a significant negative correlation between the tumor
levels of uPA and PAI-1 and the response to tamoxifen, but they
did not analyze the uPA:PAI-1 complex levels (9). We found no
relation between efficacy of endocrine therapy and the separate
uPA and PAI-1 components, this relation was only found for the
complex levels. This is not so controversial as it may seem, real-
izing that the predictive value of uPA:PAI-1 complex tumor lev-
els on theoretical grounds is superior to that of either uPA or
PAI-1, allowing statistical significant results in an even relative-
ly small group of patients.
Previous studies showed that the expression of uPA is influ-
enced by (anti-)estrogens (18-20). Xing and colleagues report-
ed that the combination of tamoxifen and the synthetic uPA
active site inhibitor B-428 had an additive anti-invasive effect in
a model in which uPA and its receptor uPAR play a key role
(18). In a study of Abidi, et al., it appeared that ER-mediated
inhibition of uPA activity by anti-estrogens may limit the gener-
ation of plasmin and the activation of other proteases (19). In
addition, Levenson, et al. found that 4-hydroxytamoxifen and
raloxifene showed agonist activity by downregulation of uPA
and PAI-1 genes in ER-transfectants (20). The exact role of
(anti-)estrogens in these processes is still under investigation.
Possibly, uPA:PAI-1 complexes might be involved in estrogen-
independent growth signalling, thereby counteracting the effica-
cy of endocrine therapy. In the human breast cancer cell-line
MCF-7, binding of PAI-1 to uPA has been shown to modify the
promigratory effect of uPA into a mitogenic signal (21).
uPA:PAI-1 complexes selectively promoted cellular growth
through sustained phosphorylation of extracellular signal-regu-
lated kinase (ERK), whereas either uPA or PAI-1 did not. Thus,
uPA:PAI-1 complexes might form an autocrine growth regula-
tory pathway leading to endocrine (tamoxifen)-resistance.
In the current study, the included patients were treated with
first-line endocrine therapy for advanced breast cancer between
1987 and 1996. In the late eighties and early nineties, first-line
endocrine therapy was also given to patients with an ER and
PgR negative (or ER and/or PgR unknown) tumor in case of
high age or poor performance status. In the current study, almost
one-fifth of the included patients treated with first-line endo-
crine therapy actually had an ER and PgR negative tumor. We
observed in this group of patients a response rate of only 11%.
A comparable low response rate was also reported in previous
studies (22, 23). Moreover, a substantial percentage of ER
and/or PgR positive patients did not respond (41%) to first-line
endocrine treatment. Therefore, additional markers are needed
to improve the ability to predict response to first-line endocrine
therapy. The present findings indicate that the presence of high
tumor levels of uPA:PAI-1 complex in ER and/or PgR positive
tumors was associated with a reduced response to first-line
endocrine treatment from 59% to 35%, while low levels of
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uPA:PAI-1 complex in ER and/or PgR positive tumors resulted
in an increased response rate from 59% to 72%. Therefore,
advanced breast cancer patients with tumors that are ER and/or
PgR positive and that have high levels of uPA:PAI-1 complex
might benefit from a future approach of a combined therapy that
consists of both endocrine therapy and specific therapy directed
against the plasminogen activation system.
In the current study we also investigated whether the tumor
levels of components of the plasminogen activation system
were predictive for the responsiveness to first-line chemothera-
py. Harbeck, et al. found an association between components of
the plasminogen activation system and responsiveness to
chemotherapy in the adjuvant setting, i.e. patients with high
tumor tissue levels of both uPA and PAI-1 benefited more
strongly from conventional adjuvant chemotherapy than those
with low levels (7, 8). We found no such association with palli-
ative chemotherapy.
In conclusion, according to our results, increased tumor lev-
els of uPA:PAI-1 complex predict a reduced response to first-
line endocrine therapy in patients with advanced breast cancer,
independent of steroid hormone receptor status. Understanding
and influencing this underlying resistance to endocrine therapy
may ultimately improve outcome in this specific group of
patients. 
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